North China Pharmaceutical Company.Ltd (SHA:600812)

China flag China · Delayed Price · Currency is CNY
5.53
+0.03 (0.55%)
Feb 24, 2026, 3:00 PM CST
Market Cap9.44B +3.4%
Revenue (ttm)9.79B +0.9%
Net Income183.03M +130.6%
EPS0.11 +113.5%
Shares Out1.72B
PE Ratio51.91
Forward PEn/a
Dividend0.03 (0.55%)
Ex-Dividend Daten/a
Volume7,405,717
Average Volume19,399,243
Open5.54
Previous Close5.50
Day's Range5.51 - 5.55
52-Week Range5.32 - 7.46
Beta0.48
RSI38.22
Earnings DateApr 18, 2026

About SHA:600812

North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China. [Read more]

Sector Healthcare
Founded 1992
Employees 10,000
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600812
Full Company Profile

Financial Performance

In 2024, SHA:600812's revenue was 9.87 billion, a decrease of -2.48% compared to the previous year's 10.12 billion. Earnings were 126.99 million, an increase of 2496.79%.

Financial Statements